Compare ALKT & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALKT | RAPP |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2021 | 2024 |
| Metric | ALKT | RAPP |
|---|---|---|
| Price | $16.48 | $41.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $28.57 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 2.3M | 436.6K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,159,000.00 | N/A |
| Revenue This Year | $21.85 | N/A |
| Revenue Next Year | $16.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 35.68 | N/A |
| 52 Week Low | $13.98 | $13.64 |
| 52 Week High | $28.53 | $44.28 |
| Indicator | ALKT | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 54.13 |
| Support Level | $16.10 | $33.54 |
| Resistance Level | $17.81 | $43.70 |
| Average True Range (ATR) | 0.80 | 2.88 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 3.76 | 49.05 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.